Special Drug Use Investigation for LAMICTAL Bipolar

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This post-marketing surveillance study is designed to collect and assess information on safety and effectiveness of lamotrigine tablets in patients with bipolar disorder in routine clinical practice.

("LAMICTAL" is a trademark of the GlaxoSmithKline group of companies.)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Lamotrigine

Criteria

Inclusion Criteria:

• Patients with bipolar disorder

• Patients treated with lamotrigine tablets for the first time

Exclusion Criteria:

• Not applicable